Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 3/20 | 0.41 |
| ▸ | PIK3R2 | O00459 | 3/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.41 |
| ▸ | PIK3R5 | Q8WYR1 | 3/20 | 0.41 |
| ▸ | PIK3R3 | Q92569 | 3/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 7/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3555260 | 0.82 | MAPK1 (0.43) | PIK3CDPIK3R2PIK3CAPIK3CBPIK3CG | |
| SCHEMBL21623340 | 0.79 | S1PR2 (0.37) | USP30GPR119 | |
| SCHEMBL4407107 | 0.76 | MAPK1 (0.44) | USP30GPR119JAK2JAK1MAPK1 | |
| SCHEMBL4408213 | 0.75 | USP30 (0.43) | USP30GPR119EGFRSRCCHRM2 | |
| SCHEMBL20986856 | 0.74 | PIK3CD (0.47) | PIK3CDPIK3R2PIK3CAPIK3CBPIK3CG | |
| SCHEMBL20986857 | 0.74 | PIK3CD (0.47) | PIK3CDPIK3R2PIK3CAPIK3CBPIK3CG | |
| SCHEMBL23512959 | 0.73 | USP2 (0.42) | USP30GPR119CHRM2CHRM1CHRM3 | |
| SCHEMBL26041166 | 0.73 | USP2 (0.42) | USP30GPR119CHRM2CHRM1CHRM3 | |
| SCHEMBL15202871 | 0.73 | USP2 (0.42) | USP30GPR119CHRM2CHRM1CHRM3 | |
| SCHEMBL31026108 | 0.72 | POLB (0.46) | PIK3CAUSP30GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318412-A1 | Tricyclic heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318412-A1 | Tricyclic heterocyclic compound and use thereof | HTR2C, HTR2A, HTR5A | PIK3CD 1770/4885PIK3R2 1645/4885PIK3CA 2213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.